Posts By :

admpmccbiobank

2022 | Cardiovascular Signatures of COVID-19 Predict Mortality and Identify Barrier Stabilizing Therapies

 150 150 admpmccbiobank
By:
0

Short Description: Endothelial cell (EC) activation, endotheliitis, vascular permeability, and thrombosis have been observed in patients with severe COVID-19, indicating that the vasculature is affected during the acute stages of SARS-CoV-2 infection. Results from this study indicated that multiple inflammatory and EC activation biomarkers were associated with mortality in COVID-19 patients and in severity-matched SARS-CoV-2-negative patients, while dysregulation of specific microRNAs at presentation was specific for poor COVID-19-related outcomes and revealed disease-relevant pathways.
Interest: COVID-19, Respiratory Disease, Stroke and Cardiovascular, Vascular
Click Here to Read the Full Publication

2022 | Combined Cardiac Fluorodeoxyglucose-Positron Emission Tomography/Magnetic Resonance Imaging Assessment of Myocardial Injury in Patients Who Recently Recovered From COVID-19

 150 150 admpmccbiobank
By:
0

Short Description: There is limited understanding of changes with myocardial metabolism in patients who have recovered from acute COVID-19. In this paper, we examine myocardial metabolic changes early after recovery from COVID-19 using fluorodeoxyglucose-positron emission tomography (PET) and associate these changes to abnormalities in cardiac magnetic resonance imaging (MRI)-based function and tissue characterization measures and inflammatory blood markers.
Interest: Cardiac Imaging, COVID-19, Medical Imaging, Myocardial Injury, Respiratory Disease
Click Here to Read the Full Publication

2021 | Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment

 150 150 admpmccbiobank
By:
0

Short Description: A case report of recurrent myocarditis in a patient previously treated with a programmed death ligand I inhibitor, an immune checkpoint inhibitor that blocks the binding of PD-L1 to programmed cell death protein 1 and CD80.
Interest: Cancer, Cardio-Oncology, Cardiology, Heart disease, Myocarditis
Click Here to Read the Full Publication